Nitric oxide in the normal kidney and in patients with diabetic nephropathy

被引:59
作者
Tessari, Paolo [1 ]
机构
[1] Univ Padua, Div Metab, Dept Med, Via Giustiniani 2, I-35128 Padua, Italy
关键词
Arginine; Diabetes mellitus; Nephropathy; Nitric oxide; Stable isotopes; Vascular disease; SYNTHASE GENE POLYMORPHISMS; L-ARGININE; ASYMMETRIC DIMETHYLARGININE; ENDOTHELIAL FUNCTION; GLOMERULAR HYPERFILTRATION; INSULIN-RESISTANCE; THERAPEUTIC TOOL; OXIDATIVE STRESS; FOREARM LEUCINE; BLOOD-PRESSURE;
D O I
10.1007/s40620-014-0136-2
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Nitric oxide (NO) is a gas with biological and regulatory properties, produced from arginine by the way of nitric oxide synthases (NOS), and with a very short half-life (few seconds). A "coupled" NOS activity leads to NO generation, whereas its uncoupling produces the reactive oxygen species peroxynitrite (ONOO-). Uncoupling is usually due to inflammation, oxidative stress, decreased cofactor availability, or excessive NO production. Competitive inhibitors of NO production are post-translationally methylated arginine residues in proteins, which are constantly released into the circulation. NO availability is altered in many clinical conditions associated with vascular dysfunction, such as diabetes mellitus. The kidney plays an important role in body NO homeostasis. This article provides an overview of current literature, on NO production/availability, with a focus on diabetic nephropathy. In diabetes, NO availability is usually decreased (with exception of the early, hyper filtration phase of nephropathy in Type 1 diabetes), and it could constitute a factor of the generalized vasculopathy present in diabetic nephropathy. NO generation in Type 2 diabetes with nephropathy is inversely associated with the dimethyl-arginine concentrations, which are therefore important modulators of NO synthesis independently from the classic stimulatory pathways (such as the insulin effect). A disturbed NO metabolism is present in diabetes associated with nephropathy. Although modulation of NO production is not yet a common therapeutical strategy, a number of yet experimental compounds need to be tested as potential interventions to treat the vascular dysfunction and nephropathy in diabetes, as well as in other diseased states. Finally, in diabetic nephropathy NO deficiency may be associated to that of hydrogen sulfide, another interesting gaseous mediator which is increasingly investigated.
引用
收藏
页码:257 / 268
页数:12
相关论文
共 123 条
[1]   Sequence Variation in DDAH1 and DDAH2 Genes Is Strongly and Additively Associated with Serum ADMA Concentrations in Individuals with Type 2 Diabetes [J].
Abhary, Sotoodeh ;
Burdon, Kathryn P. ;
Kuot, Abraham ;
Javadiyan, Shahrbanou ;
Whiting, Malcolm J. ;
Kasmeridis, Nicholas ;
Petrovsky, Nikolai ;
Craig, Jamie E. .
PLOS ONE, 2010, 5 (03)
[2]   Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64) [J].
Adler, AI ;
Stevens, RJ ;
Manley, SE ;
Bilous, RW ;
Cull, CA ;
Holman, RR .
KIDNEY INTERNATIONAL, 2003, 63 (01) :225-232
[3]   A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy [J].
Agarwal, R ;
Saha, C ;
Battiwala, M ;
Vasavada, N ;
Curley, T ;
Chase, SD ;
Sachs, N ;
Semret, MH .
KIDNEY INTERNATIONAL, 2005, 68 (01) :285-292
[4]  
Altaany Z, 2014, CURR MED CHEM
[5]   Urinary sulphate excretion and progression of diabetic nephropathy in Type1 diabetes [J].
Andresdottir, G. ;
Bakker, S. J. L. ;
Hansen, H. P. ;
Parving, H-H ;
Rossing, P. .
DIABETIC MEDICINE, 2013, 30 (05) :563-566
[6]  
[Anonymous], 2004, DIABETES CARE, V27, pS79
[7]  
Arima S, 2002, J AM SOC NEPHROL, V13, P342, DOI 10.1681/ASN.V132342
[8]   Renoprotective Effect of Pioglitazone by the Prevention of Glomerular Hyperfiltration through the Possible Restoration of Altered Macula Densa Signaling in Rats with Type 2 Diabetic Nephropathy [J].
Asakura, Juko ;
Hasegawa, Hajime ;
Takayanagi, Kaori ;
Shimazu, Tomokazu ;
Suge, Rie ;
Shimizu, Taisuke ;
Iwashita, Takatsugu ;
Tayama, Yosuke ;
Matsuda, Akihiko ;
Kanozawa, Koichi ;
Araki, Nobuo ;
Mitarai, Tetsuya .
NEPHRON EXPERIMENTAL NEPHROLOGY, 2012, 122 (3-4) :83-94
[9]   Molecular sites of regulation of expression of the rat cationic amino acid transporter gene [J].
Aulak, KS ;
Liu, J ;
Wu, JY ;
Hyatt, SL ;
Puppi, M ;
Henning, SJ ;
Hatzoglou, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (47) :29799-29806
[10]   L-arginine-nitric oxide kinetics in nonnal and type 2 diabetic subjects -: A stable-labelled 15N arginine approach [J].
Avogaro, A ;
Toffolo, G ;
Kiwanuka, E ;
de Kreutzenberg, SV ;
Tessari, P ;
Cobelli, C .
DIABETES, 2003, 52 (03) :795-802